secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2024-11-15T23:59:59+00:00
Accession:  0001171843-24-006400
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus reports 50% functional cure in HBsAg<1000 IU/mL patients with imdusiran + IFN in Phase 2a
--------------------------------------------------------------------------------

- Cohort A1: 50% (3/6) functional cure in HBeAg-negative patients with baseline HBsAg <1000 IU/mL; overall 25% (3/12).
- IM-PROVE II Group C: 23% (3/13) achieved HBsAg loss at Week 48 with imdusiran, VTP-300 and low-dose nivolumab.
- Both regimens generally well-tolerated; no imdusiran/IFN-related SAEs or discontinuations in IM-PROVE I.
- Data to be presented at AASLD The Liver Meeting 2024 on November 18. Corporate presentation updated on website.
- Combination of imdusiran and interferon shows potential for finite curative treatment in chronic HBV.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184324006400/0001171843-24-006400-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184324006400/f8k_111524.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-006400

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer